| Primary |
| Product Used For Unknown Indication |
42.9% |
| Drug Use For Unknown Indication |
24.6% |
| Acute Coronary Syndrome |
5.6% |
| Unevaluable Event |
4.8% |
| Myocardial Infarction |
3.2% |
| Cardiac Failure Nos |
2.4% |
| Infection |
2.4% |
| Thrombosis Prophylaxis |
2.4% |
| Anticoagulant Therapy |
1.6% |
| Atrial Fibrillation |
1.6% |
| Hiatus Hernia |
1.6% |
| Hypertension Arterial |
1.6% |
| Major Depression |
1.6% |
| Stent Placement |
1.6% |
| Dyslipidemia |
0.8% |
| Dyspnoea On Effort |
0.8% |
| Prostatitis |
0.8% |
|
| Renal Failure Acute |
10.5% |
| Dyspnoea |
5.3% |
| Hemiplegia |
5.3% |
| Hepatitis Cholestatic |
5.3% |
| Neutropenia |
5.3% |
| Operative Haemorrhage |
5.3% |
| Pancreatitis Acute |
5.3% |
| Physical Disability |
5.3% |
| Pulmonary Fibrosis |
5.3% |
| Puncture Site Haemorrhage |
5.3% |
| Renal Failure |
5.3% |
| Retroperitoneal Haematoma |
5.3% |
| Shock Haemorrhagic |
5.3% |
| Tachycardia |
5.3% |
| Thrombocythaemia |
5.3% |
| Thrombosis In Device |
5.3% |
| Tinnitus |
5.3% |
| Vascular Purpura |
5.3% |
|
| Secondary |
| Drug Use For Unknown Indication |
30.5% |
| Product Used For Unknown Indication |
29.5% |
| Hypertension |
7.8% |
| Myocardial Infarction |
4.1% |
| Atrial Fibrillation |
3.6% |
| Thrombosis Prophylaxis |
3.3% |
| Prophylaxis |
2.7% |
| Depression |
2.0% |
| Type 2 Diabetes Mellitus |
1.9% |
| Acute Coronary Syndrome |
1.8% |
| Unevaluable Event |
1.6% |
| Pain |
1.6% |
| Hypercholesterolaemia |
1.5% |
| Cardiac Failure |
1.3% |
| Dyslipidaemia |
1.3% |
| Hypothyroidism |
1.2% |
| Coronary Arterial Stent Insertion |
1.2% |
| Angina Pectoris |
1.1% |
| Diabetes Mellitus |
1.0% |
| Gastrooesophageal Reflux Disease |
1.0% |
|
| Thrombocytopenia |
13.9% |
| Renal Failure Acute |
11.8% |
| Toxic Skin Eruption |
8.2% |
| Renal Failure |
6.4% |
| Vomiting |
6.4% |
| Rectal Haemorrhage |
5.9% |
| Subdural Haematoma |
5.2% |
| International Normalised Ratio Increased |
4.2% |
| Gastrointestinal Haemorrhage |
4.0% |
| Haematoma |
4.0% |
| Melaena |
4.0% |
| Muscle Haemorrhage |
3.8% |
| Shock Haemorrhagic |
3.5% |
| Hepatitis Cholestatic |
3.1% |
| Malaise |
3.1% |
| Eosinophilic Pneumonia |
2.8% |
| Anaemia |
2.6% |
| Petechiae |
2.6% |
| Cytolytic Hepatitis |
2.4% |
| Off Label Use |
2.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
26.9% |
| Drug Use For Unknown Indication |
24.1% |
| Hypertension |
13.5% |
| Prophylaxis |
3.2% |
| Type 2 Diabetes Mellitus |
2.8% |
| Thrombosis Prophylaxis |
2.6% |
| Pain |
2.5% |
| Depression |
2.4% |
| Multiple Myeloma |
2.3% |
| Hiv Infection |
2.3% |
| Atrial Fibrillation |
2.2% |
| Hypercholesterolaemia |
2.2% |
| Diabetes Mellitus |
2.0% |
| Plasma Cell Myeloma |
1.9% |
| Myocardial Infarction |
1.8% |
| Rheumatoid Arthritis |
1.6% |
| Cardiac Failure |
1.6% |
| Dyslipidaemia |
1.4% |
| Anxiety |
1.4% |
| Osteoporosis |
1.3% |
|
| Renal Failure Acute |
12.9% |
| Vomiting |
10.0% |
| Thrombocytopenia |
9.7% |
| Renal Failure |
8.5% |
| Weight Decreased |
6.1% |
| Somnolence |
5.9% |
| Hyponatraemia |
5.2% |
| Rhabdomyolysis |
4.9% |
| Toxic Skin Eruption |
4.8% |
| Malaise |
4.3% |
| Cytolytic Hepatitis |
4.1% |
| Pyrexia |
3.5% |
| Fall |
2.7% |
| Syncope |
2.7% |
| Vertigo |
2.6% |
| Myocardial Infarction |
2.5% |
| Rash Maculo-papular |
2.5% |
| Pulmonary Embolism |
2.4% |
| Urinary Tract Infection |
2.4% |
| Urticaria |
2.4% |
|
| Interacting |
| Drug Use For Unknown Indication |
28.9% |
| Product Used For Unknown Indication |
27.7% |
| Atrial Fibrillation |
7.2% |
| Prophylaxis |
4.4% |
| Thrombosis Prophylaxis |
4.1% |
| Pain |
3.5% |
| Coronary Artery Disease |
2.8% |
| Hypertension |
2.8% |
| Angina Pectoris |
2.2% |
| Coronary Angioplasty |
2.2% |
| Dyslipidaemia |
1.9% |
| Hypercholesterolaemia |
1.9% |
| Urinary Tract Infection |
1.6% |
| Acute Coronary Syndrome |
1.3% |
| Cardiac Failure |
1.3% |
| Coronary Arterial Stent Insertion |
1.3% |
| Embolism |
1.3% |
| Hypertensive Heart Disease |
1.3% |
| Myalgia |
1.3% |
| Spinal Compression Fracture |
1.3% |
|
| Rectal Haemorrhage |
21.7% |
| International Normalised Ratio Increased |
12.0% |
| Melaena |
8.4% |
| Subdural Haematoma |
8.4% |
| Drug Interaction |
4.8% |
| Overdose |
4.8% |
| Pain In Extremity |
4.8% |
| Renal Failure |
4.8% |
| Epistaxis |
3.6% |
| Vomiting |
3.6% |
| Gastric Haemorrhage |
2.4% |
| Haemoptysis |
2.4% |
| Hypokalaemia |
2.4% |
| Partial Seizures |
2.4% |
| Subcutaneous Haematoma |
2.4% |
| Syncope |
2.4% |
| Thrombocytopenia |
2.4% |
| Thrombosis |
2.4% |
| Traumatic Haematoma |
2.4% |
| Fall |
1.2% |
|
